Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.
You may also be interested in...
Faced With Adverse Patent Rulings, Pfizer Voices Concern About India’s Deteriorating Business Environment
After having its patent for Sutent revoked, Pfizer questions India’s commitment to the WTO, saying foreign companies cannot compete fairly in the country.
Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.
Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.